Abstract:Introduction After decades of stumbling clinical development, the first gene therapies for haemophilia A and B have been commercialized and have normalized factor (F)VIII and factor (F)IX levels in some individuals in the long term. Several other clinical programs testing adeno‐associated viral (AAV) vector gene therapy are at various stages of clinical testing. Discussion Multiyear follow‐up in phase 1/2 and 3 studies showed long‐term and sometimes curative but widely variable and unpredictable efficacy. Liver toxicities, mostly low‐grade, occur in the 1st year in at least some individuals in all haemophilia A and B trials and are poorly understood. Wide variability and unpredictability of outcome and slow decline of FVIII levels are a major disadvantage because immune responses to AAV vectors preclude repeat dosing, which otherwise could improve suboptimal or restore declining expression, while overexpression may predispose to thrombosis. Long‐term safety outcomes will need lifelong monitoring because AAV vectors infused at high doses integrate into chromosomes at rates that raise questions about potential oncogenicity and necessitate vigilance. Alternative gene transfer systems employing gene editing and/or non‐viral vectors are under development and promise to overcome some limitations of the current state of the art for both haemophilia A and B. Conclusions AAV gene therapies for haemophilia have now become new treatment options but not universal cures. AAV is a powerful but imperfect gene transfer platform. Biobetter FVIII transgenes may help solve some problems plaguing gene therapy for haemophilia A. Addressing variability and unpredictability of efficacy, and delivery of gene therapy to ineligible patient subgroups may require different gene transfer systems, most of which are not ready for clinical translation yet but bring innovations needed to overcome the current limitations of gene therapy.

Hemophilia Gene Therapy: New Development from Bench to Bed Side.

Hemophilia Gene Therapy: from Bench to Bed Side.

Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Gene therapy for hemophilia: looking beyond factor expression

The bio-therapy and gene-therapy of hemophilia B in China

Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives

[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]

Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy

Current status and progress in gene therapy for hemophilia B

[Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology]

Research Progress of for Non-viral Gene Therapy for Hemophilia

Current and emerging Gene Therapies for Haemophilia A and B

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Gene therapy and gene editing strategies in inherited blood disorders

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review

Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight

Gene Therapies for Hemoglobinopathies: Promises and Challenges

Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy

AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials